<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124547">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02103673</url>
  </required_header>
  <id_info>
    <org_study_id>102-0035C</org_study_id>
    <nct_id>NCT02103673</nct_id>
  </id_info>
  <brief_title>DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan: National Science Council</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The population of dementia is increasing rapidly. Cognitive impairment as well as Behavioral
      and psychological symptoms of dementia (BPSD) add heavy burdens to caregiver. NMDA
      activation is critical for learning and memory. Individuals with Alzheimer's disease (AD)
      have fewer NMDA receptors in the frontal cortex and hippocampus than controls. This study is
      a randomized, double-blind, placebo-controlled drug trial. All patients will be allocated
      randomly to two groups: (1) NMDA enhancer: DAOIB (starting dosage: 250-500 mg/day), (2)
      placebo, for 6 weeks. The investigators hypothesize that DAOIB may yield better efficacy
      than placebo for cognitive function and clinical symptoms in patients with BPSD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Behavioral Pathology in Alzheimer's Disease Rating Scale</measure>
    <time_frame>weeks 0, 2, 4, 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Behavioral Pathology in Alzheimer's Disease Rating Scale at weeks 2, 4 and 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - cognitive subscale</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Alzheimer's Disease Assessment Scale - cognitive subscale at week 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatirc Inventory</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Neuropsychiatirc Inventory at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activities of Daily Living</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline in Instrumental Activities of Daily Living at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zarit Caregiver Burden Interview</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline in Zarit Caregiver Burden Interview at week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Geriatric Depression Scale</measure>
    <time_frame>weeks 0, 2, 4, 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline in Geriatric Depression Scale at weeks 2, 4 and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental Status Examination</measure>
    <time_frame>weeks 0 and 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline in Mini-Mental Status Examination at week 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Behavioral and Psychological Symptoms in Alzheimer's Disease</condition>
  <condition>Behavioral and Psychological Symptoms in Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>DAOIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth per day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAOIB</intervention_name>
    <description>Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks</description>
    <arm_group_label>DAOIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention drug: placebo by mouth. Duration: 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of probable Alzheimer's disease or probable vascular dementia

          -  For patients with vascular dementia, the post-stroke period must be more than 3
             months

          -  Mini-Mental State scores between 5-26

          -  Clinical Dementia Rating score equal to or greater than 1

          -  Behavioral Pathology in Alzheimer's Disease Rating Scale score equal to or greater
             than 2

        Exclusion Criteria:

          -  Current substance abuse or history of substance dependence in the past 6 months

          -  Other major psychiatric diagnoses, such as schizophrenia, major depressive disorder,
             bipolar disorder and mental retardation etc.

          -  Serious medical or neurological illness other than Alzheimer's disease/vascular
             dementia and other secondary dementia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsien-Yuan Lane, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>China Medical University Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsien-Yuan Lane, MD, PhD</last_name>
    <phone>886-4-22052121</phone>
    <phone_ext>1074</phone_ext>
    <email>hylane@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Hsin Lin, MD, PhD</last_name>
      <phone>886-7-7317123</phone>
      <phone_ext>8753</phone_ext>
      <email>cyndi36@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chieh-Hsin Lin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsien-Yuan Lane, MD, PhD</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>1074</phone_ext>
      <email>hylane@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hsien-Yuan Lane, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chieh-Hsin Lin</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
